These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36131190)

  • 41. Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.
    Sibum I; Hagedoorn P; Kluitman MPG; Kloezen M; Frijlink HW; Grasmeijer F
    Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31881695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.
    Mehanna MM; Mohyeldin SM; Elgindy NA
    Int J Nanomedicine; 2019; 14():9089-9112. PubMed ID: 31819421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.
    Braunstein M; Hickey AJ; Ekins S
    Pharm Res; 2019 Oct; 36(12):166. PubMed ID: 31650321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant.
    Maretti E; Rustichelli C; Lassinantti Gualtieri M; Costantino L; Siligardi C; Miselli P; Buttini F; Montecchi M; Leo E; Truzzi E; Iannuccelli V
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
    Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
    Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of rifampicin treatment for tuberculosis.
    Grobbelaar M; Louw GE; Sampson SL; van Helden PD; Donald PR; Warren RM
    Infect Genet Evol; 2019 Oct; 74():103937. PubMed ID: 31247337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation.
    Sibum I; Hagedoorn P; Frijlink HW; Grasmeijer F
    Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31086107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.
    Rossi I; Buttini F; Sonvico F; Affaticati F; Martinelli F; Annunziato G; Machado D; Viveiros M; Pieroni M; Bettini R
    Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31052403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
    Momin MAM; Sinha S; Tucker IG; Das SC
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy.
    Cunha L; Rodrigues S; Rosa da Costa AM; Faleiro ML; Buttini F; Grenha A
    Polymers (Basel); 2018 Jun; 10(6):. PubMed ID: 30966670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
    Seijger C; Hoefsloot W; Bergsma-de Guchteneire I; Te Brake L; van Ingen J; Kuipers S; van Crevel R; Aarnoutse R; Boeree M; Magis-Escurra C
    PLoS One; 2019; 14(3):e0213718. PubMed ID: 30870476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
    Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
    AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis.
    Scolari IR; Páez PL; Sánchez-Borzone ME; Granero GE
    AAPS PharmSciTech; 2019 Jan; 20(2):67. PubMed ID: 30627867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.
    Chorepsima S; Kechagias KS; Kalimeris G; Triarides NA; Falagas ME
    Drug Des Devel Ther; 2018; 12():4059-4066. PubMed ID: 30568427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
    O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
    Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The present state of the tuberculosis drug development pipeline.
    J Libardo MD; Boshoff HI; Barry CE
    Curr Opin Pharmacol; 2018 Oct; 42():81-94. PubMed ID: 30144650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preparation and optimization of a dry powder for inhalation of second-line anti-tuberculosis drugs.
    Ranjan R; Srivastava A; Bharti R; Ray L; Singh J; Misra A
    Int J Pharm; 2018 Aug; 547(1-2):150-157. PubMed ID: 29852204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
    Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
    Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.